钠-葡萄糖共转运蛋白抑制剂的新作用

The Prescriber Pub Date : 2022-10-01 DOI:10.1002/psb.2014

A. Barton

{"title":"钠-葡萄糖共转运蛋白抑制剂的新作用","authors":"A. Barton","doi":"10.1002/psb.2014","DOIUrl":null,"url":null,"abstract":"Originally introduced as antidiabetic agents, the use of sodium‐glucose co‐transporter protein (SGLT) inhibitors has now expanded to a wider range of indications, including heart failure and chronic kidney disease, following positive clinical trial outcomes. This article summarises the properties of SGLT inhibitors and the increasing evidence base for their use in many cardiovascular and renal conditions.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"99 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Emerging roles of sodium‐glucose co‐transporter inhibitors\",\"authors\":\"A. Barton\",\"doi\":\"10.1002/psb.2014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Originally introduced as antidiabetic agents, the use of sodium‐glucose co‐transporter protein (SGLT) inhibitors has now expanded to a wider range of indications, including heart failure and chronic kidney disease, following positive clinical trial outcomes. This article summarises the properties of SGLT inhibitors and the increasing evidence base for their use in many cardiovascular and renal conditions.\",\"PeriodicalId\":88184,\"journal\":{\"name\":\"The Prescriber\",\"volume\":\"99 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/psb.2014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

钠-葡萄糖共转运蛋白(SGLT)抑制剂最初是作为抗糖尿病药物引入的，随着积极的临床试验结果，现在已扩展到更广泛的适应症，包括心力衰竭和慢性肾脏疾病。本文综述了SGLT抑制剂的特性，以及越来越多的证据表明它们在许多心血管和肾脏疾病中的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Emerging roles of sodium‐glucose co‐transporter inhibitors

Originally introduced as antidiabetic agents, the use of sodium‐glucose co‐transporter protein (SGLT) inhibitors has now expanded to a wider range of indications, including heart failure and chronic kidney disease, following positive clinical trial outcomes. This article summarises the properties of SGLT inhibitors and the increasing evidence base for their use in many cardiovascular and renal conditions.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Prescriber

自引率

0.00%

发文量

期刊最新文献

MAOI prescribing: separating misconceptions from reality Understanding liver function tests: part 1 Diagnosis and management of type 2 diabetes in children Is the NHS ready for new Alzheimer's disease treatments? Prescribing Skills Assessment